Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
2024年5月14日 - 5:30AM
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a
clinical-stage biotechnology company pioneering mRNA cell therapy
for autoimmune diseases, today announced that management will
participate in a fireside chat at the H.C. Wainwright 2nd Annual
BioConnect Investor Conference on Monday, May 20, 2024, at 3:00
p.m. ET.
A live webcast of the fireside chat is expected to be accessible
in the Events section of the Company’s website at
www.cartesiantherapeutics.com, where an archived replay of the
event will be accessible for a limited time.
About Cartesian TherapeuticsCartesian
Therapeutics is a clinical-stage company pioneering mRNA cell
therapies for the treatment of autoimmune diseases. The Company’s
lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T
in Phase 2b clinical development for patients with generalized
myasthenia gravis. Additional Phase 2 studies are planned in
systemic lupus erythematosus under an allowed IND, as well as
basket trials in additional autoimmune indications. The Company’s
clinical-stage pipeline also includes Descartes-15, a
next-generation, autologous anti-BCMA mRNA CAR-T. For more
information, please visit www.cartesiantherapeutics.com or
follow the Company on LinkedIn or X, formerly known as Twitter.
Contact InformationInvestor Relations:Ron
MoldaverRon.moldaver@cartesiantx.com
Media:David RosenArgot Partnerscartesian@argotpartners.com
Cartesian Therapeutics (NASDAQ:RNAC)
過去 株価チャート
から 4 2024 まで 5 2024
Cartesian Therapeutics (NASDAQ:RNAC)
過去 株価チャート
から 5 2023 まで 5 2024